INmune Bio submits pre-MAA package for Ebstrocel, targets mid-2027 UK approval
Go back to INmune Bio submits pre-MAA package for Ebstrocel, targets mid-2027 UK approval| (NASDAQ: INMB) | Delayed: 1.61 +0.01 (0.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.60 | 52 Week High | $ | |||
| Open | $1.61 | 52 Week Low | $ | |||
| Day High | $1.69 | P/E | N/A | |||
| Day Low | $1.60 | EPS | $ | |||
| Volume | 229,971 | |||||



